Compare Novartis AG (NVS) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Xpeng Inc - ADR — how do they compare? Novartis AG trades at $152.54 (market cap $295.37B), while Xpeng Inc - ADR trades at $11.74 (market cap $11.15B). The key difference: Novartis AG is far larger — about 26.5× Xpeng Inc - ADR's market cap, and Novartis AG pays a 3.07% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals.
| NVS | XPEV | |
|---|---|---|
Market Cap | $295.37B | $11.15B |
Sector | Health | Consumer Cyclical |
52-Week High | $168.62 | $28.07 |
52-Week Low | $119.31 | $11.68 |
Enterprise Value | $336.69B | $13.28B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.
The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.
XPeng (XPEV) trades at $11.76, down 2.04% today, amid a bearish technical signal. The company reported a net loss of $1.14 billion in 2025 despite revenue growth to $76.72 billion, with profitability metrics like ROE at -7.64% remaining weak. Recent news highlights expansion into robotics and overseas markets, including a new SUV launch in Munich, while July 2026 deliveries increased 4% year-over-year to 38,027 vehicles.
The stock offers potential upside to the $17.00 analyst consensus target but faces risks from persistent losses, intense EV competition, and macroeconomic pressures. Investor sentiment is mixed, with 64.7% of analysts rating it a buy, but technical indicators suggest near-term caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
